$2.55
-0.02[-0.78%]
Last update: 6:38PM Get Real Time Here
DiaMedica Therapeutics
(NASDAQ:DMAC)Latest News for DiaMedica Therapeutics Stock (NASDAQ:DMAC)
DiaMedica Therapeutics Stock (NASDAQ: DMAC)
Categories: All
Wednesday, April 24, 2024
Wednesday, April 17, 2024
Thursday, March 21, 2024
Tuesday, March 19, 2024
Monday, November 13, 2023
Friday, November 10, 2023
Monday, August 14, 2023
Thursday, June 22, 2023
Wednesday, June 21, 2023
- DiaMedica Raises $37.5M Via Equity Offering, Aiding Development Activities For DM199Nabaparna Bhattacharya - Jun 21, 2023, 11:40AM
- DiaMedica Therapeutics Announces $37.5M Private Placement Of 11,011,406 Common Shares At A Purchase Price Of $3.40/ShareHappy Mohamed - Jun 21, 2023, 8:42AM
- DiaMedica Therapeutics Announces That The FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic StrokeHappy Mohamed - Jun 21, 2023, 8:16AM
Monday, May 22, 2023
- Diamedica Therapeutics Included In Response To FDA Is Protocol Amendment To Incorporate Reduced Dose For Intravenous Administration Of DM199Benzinga Newsdesk - May 22, 2023, 5:18PM
- Filed On May 19, DiaMedica Therapeutics A Complete Clinical Hold Response With FDA For Clinical Hold On A Phase 2/3 Clinical Trial Of DM199; Response With FDA Requesting Clinical Hold Imposed On Phase 2/3 Clinical Trial Of DM199 For AIS Be LiftedBenzinga Newsdesk - May 22, 2023, 5:17PM
Monday, May 15, 2023
Friday, May 12, 2023
Tuesday, March 28, 2023
- DiaMedica Therapeutics FY22 EPS $(0.52)Michael Horton - Mar 28, 2023, 4:36PM
- DiaMedica Therapeutics Provides A Business Update And Announces FY22 Financial Results; DiaMedica Reported Total Cash, Cash Equivalents And Investments Of $33.5MHappy Mohamed - Mar 28, 2023, 4:34PM
- Earnings Scheduled For March 28, 2023Benzinga Insights - Mar 28, 2023, 6:38AM
Monday, March 27, 2023
Friday, December 02, 2022
Wednesday, November 09, 2022
Monday, November 07, 2022
Friday, October 28, 2022
Friday, October 07, 2022
Thursday, October 06, 2022
Wednesday, August 10, 2022
- DiaMedica Therapeutics: Q2 Earnings InsightsBenzinga Insights - Aug 10, 2022, 11:28PM
- DiaMedica Therapeutics Q2 EPS $(0.13) Beats $(0.18) EstimateMichael Horton - Aug 10, 2022, 5:21PM
- Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox TrialVandana Singh - Aug 10, 2022, 11:33AM
- Earnings Scheduled For August 10, 2022Benzinga Insights - Aug 10, 2022, 5:33AM
Tuesday, August 09, 2022
Friday, July 22, 2022
Friday, July 08, 2022
Thursday, July 07, 2022
- Ten Stocks Trending on Discord for Thursday July 7, 2022: TSLA, AMZN, CTMX, AAPL, GME, RGS, DMAC, JAGX, META, TTOOCharles Gross - Jul 7, 2022, 3:41PM
- Nasdaq Surges 250 Points; Crude Oil Rises SharplyLisa Levin - Jul 7, 2022, 3:01PM
- Stocks That Hit 52-Week Lows On ThursdayBenzinga Insights - Jul 7, 2022, 12:12PM
- Dow Jumps More Than 200 Points; Samsung Sees This Much Surge In Quarterly RevenueLisa Levin - Jul 7, 2022, 12:11PM
- This EV Maker Stock Jumps More Than 9%, Here's 46 Stocks Moving In Thursday's Mid-Day SessionLisa Levin - Jul 7, 2022, 12:02PM
- Why U.S. Stocks Are Trading Higher After Rise In Jobless ClaimsLisa Levin - Jul 7, 2022, 10:23AM
- Lake Street Maintains Buy on DiaMedica Therapeutics, Lowers Price Target to $8Benzinga Newsdesk - Jul 7, 2022, 10:12AM
- Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022Benzinga Insights - Jul 7, 2022, 10:04AM
- The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 PillVandana Singh - Jul 7, 2022, 10:03AM
- Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Lowers Price Target to $12Benzinga Newsdesk - Jul 7, 2022, 10:03AM
- DiaMedica Therapeutics shares are trading lower after the company announced the FDA has placed a clinical hold on its Phase 2/3 ReMEDy2 trial for DM199.Benzinga Newsdesk - Jul 7, 2022, 9:46AM
- Oppenheimer Downgrades DiaMedica Therapeutics to PerformBenzinga Newsdesk - Jul 7, 2022, 9:15AM